Premium
Cyclic Peptides as Inhibitors of Amyloid Fibrillation
Author(s) -
Luo Jinghui,
Abrahams Jan Pieter
Publication year - 2014
Publication title -
chemistry – a european journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.687
H-Index - 242
eISSN - 1521-3765
pISSN - 0947-6539
DOI - 10.1002/chem.201304253
Subject(s) - amyloid (mycology) , fibril , fibrillation , amyloid fibril , sequence (biology) , cytotoxicity , chemistry , peptide , amyloid β , peptide sequence , p3 peptide , amino acid , cyclic peptide , disease , biochemistry , biophysics , neuroscience , alzheimer's disease , medicine , biology , amyloid precursor protein , in vitro , atrial fibrillation , inorganic chemistry , gene
Many neurodegenerative diseases, like Parkinson’s, Alzheimer’s, or Huntington’s disease, occur as a result of amyloid protein fibril formation and cell death induced by this process. Cyclic peptides (CPs) and their derivatives form a new class of powerful inhibitors that prevent amyloid fibrillation and decrease the cytotoxicity of aggregates. The strategies for designing CPs are described, with respect to their amino acid sequence and/or conformational similarity to amyloid fibrils. The implications of CPs for the study and possible treatment of amyloid‐related diseases are discussed.